The first quarter of 2024 saw 115 agreed research and development partnerships totaling $36 billion. Eight of the top ten ranked by deal value involved technology platforms for developing a broad range of therapeutics, and three included Novartis as it expands its RNA and gene-based programs. The first quarter of 2024 saw 115 agreed research and development partnerships totaling $36 billion. Eight of the top ten ranked by deal value involved technology platforms for developing a broad range of therapeutics, and three included Novartis as it expands its RNA and gene-based programs.
No takes yet. Share an insight, caveat, or question.
Monica Hoyos Flight (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: